Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by investment analysts at Royal Bank of Canada in a research note issued to investors on Thursday. They currently have a $430.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective points to a potential upside of 11.21% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. UBS cut their price objective on shares of Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, September 21st. Canaccord Genuity restated a “buy” rating and set a $522.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Credit Suisse Group restated a “buy” rating and set a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Citigroup reiterated a “buy” rating and set a $575.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 7th. Finally, Guggenheim reiterated a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $465.40.

Regeneron Pharmaceuticals (REGN) opened at $386.67 on Thursday. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The firm has a market cap of $41,011.62, a PE ratio of 33.05, a PEG ratio of 1.50 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same period last year, the business earned $3.13 earnings per share. Regeneron Pharmaceuticals’s revenue was up 23.0% compared to the same quarter last year. research analysts anticipate that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.

In other news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now directly owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 32.3% during the 2nd quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 80 shares during the period. Korea Investment CORP increased its position in Regeneron Pharmaceuticals by 223.9% during the 1st quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 206 shares in the last quarter. Advisory Services Network LLC increased its position in Regeneron Pharmaceuticals by 5,433.3% during the 2nd quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 326 shares in the last quarter. WFG Advisors LP increased its position in Regeneron Pharmaceuticals by 12,358.3% during the 4th quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 7,415 shares in the last quarter. Finally, Fieldpoint Private Securities LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $130,000. Institutional investors and hedge funds own 66.67% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/14/regeneron-pharmaceuticals-regn-earns-hold-rating-from-royal-bank-of-canada.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.